New combo tackles tough colorectal cancer in small trial
NCT ID NCT03828799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two treatments (regorafenib and FOLFIRINOX) in 13 people with a type of advanced colorectal cancer that has a specific gene change (RAS mutation). The main goal was to see if the combination was safe and tolerable. The study also looked at how long the cancer stayed under control. This is not a cure, but aims to manage the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Antoine Lacassagne
Nice, Alpes-Maritimes, 06189, France
-
Centre Cario - HPCA
Plérin, Finistère, 22190, France
-
Centre Georges-François Leclerc
Dijon, Côte d'Or, 21079, France
-
Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier, 34298, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?